Thailand Charter of Health and Suranaree University Join Forces with Japan’s Batfa Inc. for Groundbreaking Cancer Research

Bangkok, Thailand – September 2, 2024 – The Thailand Charter of Health (TCH), in partnership with Suranaree University of Technology and Japan’s Batfa Japan Inc., has signed a Memorandum of Understanding (MOU) to spearhead innovative cancer research and treatment. The agreement, signed during an international conference at Panacee Hospital Rama II, marks a significant step in advancing non-toxic cancer therapies and health innovation.

Harnessing Educational Excellence for Cancer Research

**Aerial view of Suranaree University of Technology**, a leading institution known for its innovation and commitment to advancing research in health and technology, playing a pivotal role in collaborative cancer research initiatives.

Suranaree University of Technology, a leading institution known for its focus on innovation and entrepreneurship, will take a pivotal role in the research aspect of this collaboration. With a strong commitment to developing advanced health solutions, the university will lead efforts in exploring new treatments, particularly in the field of non-toxic cancer therapies. Its expertise in research and education provides a solid foundation for driving forward groundbreaking discoveries in cancer treatment.

This collaboration underscores Suranaree University’s status as a key player in Thailand’s health innovation landscape, combining academic excellence with practical, real-world applications that have the potential to significantly impact cancer care.

Thailand Charter of Health: Leading Global Health Partnerships

As the primary facilitator of this MOU, the Thailand Charter of Health continues to demonstrate its capability in bridging international partnerships to advance global health solutions. TCH’s involvement in bringing together industry and academia exemplifies its mission to foster innovation and connection across borders.

The MOU focuses on developing non-toxic and integrative health solutions, leveraging Suranaree University’s research capacity, Batfa Japan’s technological support, and PANACEE BY BIOSKY’s clinical expertise. This collaboration is poised to generate significant advancements in the treatment of cancer and aging-related diseases.

**From left to right**: Apichart Paphanpuwong, CEO of PANACEE-BIOSKY; Dr. Sura Wisetsak, M.D., Director General of the Department of Health Service Support; Dr. Kampon Sriwatanakul, Chairman of the Thailand Charter of Health; Dr. Takashi Nakamura, Ph.D., from Asai Germanium Research Institute; Dr. Mullika Sungsanit, Vice Rector for Engagement, Innovation, and Entrepreneurship, Suranaree University of Technology.

Recognizing Leadership and Innovation

A key highlight of the event was the recognition of key contributors through TCH’s award ceremony:

Mr. Kamaru Sasaki, President of Batfa Japan Inc., was presented with the Excellence in International Business Leadership Award for his role in fostering international collaborations.
Dr. Yasuo Komura was honored with the Excellence in Medical Leadership and Healthcare Innovation Award for his contributions to immunotherapy and innovative healthcare practices.
Dr. Takashi Nakamura received the Innovative Cancer Therapy Research Award for his pioneering research on Asaigermanium, a promising non-toxic cancer treatment.

Focus on Non-Toxic Cancer Therapies

At the heart of the conference were presentations on cutting-edge cancer therapies, highlighting integrative, non-toxic approaches. Dr. Takashi Nakamura, Director of the Hakodate R&D Center at the Asai Germanium Research Institute, presented his findings on Asaigermanium, emphasizing its potential to improve patient outcomes while minimizing harmful side effects.

Further expanding on this, Dr. Serge Jurasunas, a naturopathic doctor specializing in oncology, shared his clinical experiences using Asaigermanium in cancer treatment. Their research points towards a future where cancer therapies are both effective and less harmful, aligning with global trends toward patient-centered care.

Conclusion: A Milestone for Research and Innovation

The MOU signed between Suranaree University of Technology, the Thailand Charter of Health, and Batfa Japan Inc. represents a major milestone in the fight against cancer. By uniting the capabilities of a leading academic institution with international industry expertise, this collaboration has the potential to revolutionize cancer treatment.

The Thailand Charter of Health remains committed to driving forward innovative healthcare solutions through its global network. This partnership is a testament to TCH’s role in bridging academic research and practical applications to improve patient care and create a healthier future for all.